A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR) (ARMOR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04104321|
Recruitment Status : Suspended (
Interim analysis of data from open-label part, showed this part of the study met its objectives, therefore decided to discontinue this part.
Starting the double-blind part is being delayed due to Aramchol Meglumine being formulated.)
First Posted : September 26, 2019
Last Update Posted : August 4, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
An Open-Label Part is added:
This part will enroll in selected sites which are less affected by the COVID-19 pandemic.
150 subjects with NASH and fibrosis confirmed by liver histology (F1-F3) will be randomized into 3 groups according to the post-baseline biopsy.
The objective of the Open-Label Part is:
- To evaluate the safety and PK of twice daily administration (BID) of Aramchol 300mg in subjects with NASH and liver fibrosis.
- To explore the kinetics of histological outcome measures and Non-Invasive Tests (NITs) associated with NASH and fibrosis for the treatment duration of 24, 48 and 72 weeks.
All patients will be allocated to Aramchol.
Double Blind Part:
This part is double blind, placebo controlled randomized in subjects with NASH and fibrosis stages 2-3 who are overweight or obese and have prediabetes or type 2 diabetes.
The primary objectives of this part of the study are to evaluate the effect of Aramchol as compared to placebo on NASH resolution, fibrosis improvement and clinical outcomes related to progression of liver disease.
Subjects will be randomized to receive Aramchol 300mg BID or matching placebo in a 2:1 randomization ratio.
|Condition or disease||Intervention/treatment||Phase|
|Nonalcoholic Steatohepatitis (NASH)||Drug: Aramchol Drug: Placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||2000 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||
In the Double-Blind part of the study, subjects will be randomized in a ratio of 2:1 to receive Aramchol 300mg BID or matching placebo, respectively.
In the Open Label part of the study, there will be a single group of 150 subjects (expected) all receiving Aramchol 300mg BID.
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With Nonalcoholic Steatohepatitis (NASH) With Open-Label Part to Evaluate the Safety, PK and Treatment Response Kinetics of Aramchol. The ARMOR Study|
|Actual Study Start Date :||September 23, 2019|
|Estimated Primary Completion Date :||December 2024|
|Estimated Study Completion Date :||June 2027|
Aramchol 300 mg oral tablet
Aramchol 300 mg BID
Placebo Comparator: Placebo
Placebo matching oral tablet
- Open label part: Kinetics of histological outcome measures [ Time Frame: Up to 72 or 120 weeks ]
The primary endpoints are the kinetics of the following histological outcome measures for treatment duration of 24, 48 and 72 weeks and potentially following a 2nd post-baseline biopsy at weeks 72 or 96 or 120, respectively:
- Improvement in Fibrosis defined as the Proportion (%) of subjects with improvement in liver fibrosis greater than or equal to one stage (NASH CRN fibrosis score) and no worsening of steatohepatitis (defined as no increase in NAS for ballooning, inflammation or steatosis)
- Resolution of NASH defined as the Proportion (%) of subjects with resolution of NASH (defined by ballooning of 0 and inflammation 0-1) and no worsening of liver fibrosis on NASH CRN fibrosis score (≥ 1 stage increase).
- Double Blind Part: To evaluate the effect of Aramchol compared to placebo on liver histology by assessing the following primary endpoints: [ Time Frame: 72 weeks ]
- Resolution of NASH defined as the Proportion (%) of subjects with resolution of NASH (defined by Ballooning of 0 and inflammation 0-1) and no worsening of liver fibrosis, or
- Improvement in Fibrosis defined as the Proportion (%) of subjects with improvement in liver fibrosis greater than or equal to one stage and no worsening of steatohepatitis.
- Double Blind Part: To evaluate the effect of Aramchol compared to placebo on composite long-term outcome [ Time Frame: at End of Study, latest at 5 years from last subject's randomization ]Proportion (%) of subjects experiencing at least 1 of the following events: All-cause mortality, Liver transplant, Histological progression to cirrhosis, MELD score >15, Hospitalization due to hepatic decompensation event(s).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 75 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Key Inclusion Criteria:
- Male or female age 18 to 75 years
- Histological confirmation of NASH on a diagnostic liver biopsy by central reading of the slides (biopsy obtained within 6 months prior to randomization or during the screening period)
- Total NAS Score 4 or more with at least 1 in each component of the NAS Score (steatosis ≥1 AND inflammation ≥1 AND ballooning ≥1)
- Fibrosis Stage must be 2 or 3 (Open-Label Part may include up to 30 subjects with fibrosis stage 1)
- Body mass index (BMI) between 25kg/m2 and 40 kg/m2 (Open Label part: BMI <40 kg/m2)
- AST>20 IU/L
- Type 2 diabetes mellitus or prediabetes (Open Label Part only: Type 2 diabetes or prediabetes is not an inclusion criteria)
- For subjects with type 2 diabetes, glycemia must be controlled
- Females of childbearing potential must practice a highly effective method of contraception throughout the study period and for 1 month after treatment discontinuation.
- Able to understand the nature of the study and to provide signature of the written informed consent.
Key Exclusion Criteria:
- Histologically documented liver cirrhosis (fibrosis stage 4)
- Inability or unwillingness to undergo a liver biopsy
- Abnormal synthetic liver function
- ALT or AST >5× upper limit of normal (ULN)
- Platelet count < 150,000mm3
- Alkaline phosphatase ≥2× ULN
- Known or suspected hepatocellular carcinoma (HCC)
- Model for End-Stage Liver Disease (MELD) score > 12
- Prior history or presence of decompensated liver disease
- Other (acute or chronic) coexisting liver disease based on medical history and/or centralized review of liver histology)
- Known alcohol and/or any other drug abuse or dependence in the last five years
- Weight loss of more than 5% within 3 months prior to screening
- History of bariatric surgery within 5 years of liver biopsy or planned surgery for weight reduction
- Treatment with drugs that may cause NAFLD within 12 months prior to liver biopsy
- Treatment with some anti-diabetic medications; Unless started prior to biopsy (timeframe depending on drug) and stable
- Current or planned treatment with immunosuppressive drugs
- Evidence of any other unstable or untreated clinically significant disease
- Uncontrolled hypertension
- Any other condition that in the opinion of the Investigator warrants exclusion from the study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04104321
|United States, Florida|
|The Public Health Trust of Miami-Dade County, Florida, dba the Jackson Health System|
|Miami, Florida, United States, 33136|
|United States, Texas|
|Texas Clinical Research Institute, LLC|
|Arlington, Texas, United States, 76012|
|Responsible Party:||Galmed Research and Development, Ltd.|
|Other Study ID Numbers:||
|First Posted:||September 26, 2019 Key Record Dates|
|Last Update Posted:||August 4, 2022|
|Last Verified:||June 2022|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Non-alcoholic Fatty Liver Disease
Digestive System Diseases